Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.
Roos I, Sharmin S, Ozakbas S, Alroughani R, Eichau S, Grand'Maison F, Boz C, Lechner-Scott J, Buzzard K, Prat A, Khoury SJ, Grammond P, van der Walt A, Blanco Y, Foschi M, Soysal A, Barnett M, Prevost J, Terzi M, Gerlach O, Macdonell R, Sa MJ, Spitaleri D, Laureys G, van Pesch V, John N, Cartechini E, Gouider R, Maimone D, Ramo-Tello C, Hodgkinson S, Slee M, McCombe P, Garber J, Sanchez-Menoyo JL, Al-Asmi A, Kermode AG, Lapointe E, Shaygannejad V, Van Wijmeersch B, Willekens B, Castillo-Triviño T, Taylor B, Mathey G, Le Page E, De Seze J, Ruet A, Clavelou P, Berger E, Zephir H, Kwiatkowski A, Pelletier J, Moreau T, Labauge P, Ciron J, Lebrun-Frenay C, Papeix C, Defer G, Laplaud DA, Thouvenot E, Stankoff B, Maillart E, Al-Khedr A, Bourre B, Casez O, Dos Santos A, Camdessanche JP, Hankiewicz K, Wahab A, Cabre P, Heinzlef O, Pottier C, Moulin S, Magy L, Labeyrie C, Doghri I, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups.
Roos I, et al.
CNS Drugs. 2026 Jul;40(7):1011-1025. doi: 10.1007/s40263-026-01287-8. Epub 2026 Apr 4.
CNS Drugs. 2026.
PMID: 41935174
Free PMC article.